Development and Regulatory Milestones. With respect to each of the following milestones, Ikaria shall pay BioLineRx the corresponding payment set forth below within [**] days after the achievement by Ikaria, its Affiliates or Licensees of such milestone: MILESTONE PAYMENT
Development and Regulatory Milestones. Buyer shall pay (which payments shall not be creditable against any other obligations of Buyer hereunder) a non-refundable payment for each of the milestone events set forth in this Section 3.2 (each a “Development and Regulatory Milestone”), whether the Development and Regulatory Milestone is achieved by Buyer, its Affiliates or Licensees, or any Third Party acting on behalf of Buyer, its Affiliates or Licensees. Payment for each of the Development and Regulatory Milestones shall be made only once regardless of how many times a Product achieves the corresponding Development and Regulatory Milestone, and no payment shall be due for any Development and Regulatory Milestone which is not achieved. The Development and Regulatory Milestones shall be as follows: Development and Regulatory Milestone Payment [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] Buyer shall provide Seller with written notice within thirty (30) days after the achievement of the corresponding Development and Regulatory Milestone and the payment pertaining to such Development and Regulatory Milestone shall be made by Buyer to Seller within ninety (90) days after the achievement of the corresponding Development and Regulatory Milestone.
Development and Regulatory Milestones. Celgene shall pay Vividion the following amounts after the first achievement by or on behalf of Celgene (or Vividion, solely if achieved in accordance with a Development Plan approved by Celgene or if Celgene requests (and Vividion, in its sole discretion, subject to Section 2.3, accepts) that Vividion Develop the Shared Product for the applicable development and regulatory milestone events set forth below) or its Affiliates or Licensee Partners of the corresponding development and regulatory milestone events set forth below with respect to the first Shared Product to achieve such milestone events. Milestones Payment (in US Dollars)
Development and Regulatory Milestones. (i) In partial consideration of the rights granted by Global BioLife to Prophase hereunder and subject to the terms and conditions set forth in this Agreement, Prophase shall pay to Global BioLife a milestone payment according to Section 4.02(b) after the achievement of each of the following regulatory milestones:
Development and Regulatory Milestones. Milestone Event Payment to Company 3. [***] [***]
Development and Regulatory Milestones. Licensee shall inform MedImmune within [***] Business Days after the occurrence of each of the milestone events listed below. In partial consideration of the rights granted by MedImmune to Licensee hereunder, Licensee shall pay to MedImmune the following one-time payments within [***] days after receipt of an invoice for the achievement of each of the following milestone events which shall be nonrefundable, noncreditable and fully earned upon the achievement of the applicable milestone event:
Development and Regulatory Milestones. In partial consideration of the rights granted by Xxxxxxx to Forest hereunder and subject to the terms and conditions set forth in this Agreement (including Section 6.3), Forest shall pay to Xxxxxxx the applicable milestone payment within [*] Business Days after the achievement of each of the following milestone events: Milestone Event Milestone Payment Acceptance by the FDA of an NDA for a Licensed Product $[*] Approval of an NDA for a Licensed Product in the United States and Forest does not deliver a termination notice pursuant to Section 11.2.3 with respect to the United States or this Agreement in its entirety within 10 Business Days after receipt of such approval $[*] [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Receipt of all Milestone Regulatory Approvals for a Licensed Product in a Major European Market and Forest does not deliver a termination notice pursuant to Section 11.2.3 with respect to such Major European Market or this Agreement in its entirety within 10 Business Days after receipt of such Milestone Regulatory Approvals $[*] Receipt of all Milestone Regulatory Approvals for a Licensed Product in Japan and Forest does not deliver a termination notice pursuant to Section 11.2.3 with respect to Japan or this Agreement in its entirety prior to such Milestone Regulatory Approvals $[*] Approval of an NDA (or supplement thereto) for a Licensed Product in the United States for an Indication that (a) [*] and (b) [*], and [*] (the “New Indication Milestone”) $[*]; provided that [*] If the New Indication Milestone has not already been achieved, approval of an NDA (or supplement thereto) for a Licensed Product in the United States for [*] that [*] that is [*], and [*]. For clarity, [*]. $[*]
Development and Regulatory Milestones. With respect to each Split Program, Co-Commercialized Program and Picked Validated Program selected by Celgene pursuant to Section 3.7 (or, as applicable, Section 3.3(b)(iii), Section 3.6(c) or Section 15.5), Celgene shall pay Agios the following amounts after the first achievement by or on behalf of Celgene, its Affiliates or its sublicensees of the corresponding milestone events set forth below with respect to each Licensed Product under such a Licensed Program, on a Licensed Program-by-Licensed Program basis.
Development and Regulatory Milestones. (1) Achaogen shall pay to Ark nonrefundable, noncreditable milestone payments in consideration for the achievement of the following one-time development and regulatory milestone events for the Assay: No. Event Payment [***] * For clarity, the determination as to whether milestones [***] shall be paid [***] as mutually agreed by the Parties. Also, for clarity, [***].
Development and Regulatory Milestones. During the License Term for each Licensed Program, for each milestone set forth in this Section 8.3.1 achieved by Gilead or its Affiliates or Sublicensees with respect to such Licensed Program, Gilead shall pay the corresponding non-refundable, non-creditable amount indicated for that milestone for the first instance of its achievement: Milestone Event Column I Column II Payment for First Licensed Product Payment for First Subsequent Licensed Product* (a) *** *** *** (b) *** *** *** *** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. Milestone Event Column I Column II Payment for First Licensed Product Payment for First Subsequent Licensed Product* (c) *** *** ***
